Been looking into healthcare sector ETFs lately and stumbled on something worth discussing. The XLV - Health Care Select Sector SPDR ETF - has been around for a while (launched back in 1998) and it's basically the go-to for people wanting broad exposure to the healthcare industry etf space.

What caught my attention is how massive this thing has gotten. We're talking $34.94 billion in assets, making it the largest fund tracking this segment. State Street Global Advisors runs it, and honestly, the expense ratio is hard to beat at just 0.08%. That's genuinely competitive compared to other healthcare industry etf options out there.

Looking at the portfolio breakdown - it's 100% healthcare exposure as you'd expect. The big names make up a significant chunk: Eli Lilly leads at around 12.41%, followed by Johnson & Johnson and UnitedHealth Group. Top 10 holdings account for roughly 56% of the total, so there's decent concentration but still solid diversification with about 61 total holdings.

Performance-wise, if we look back to mid-2025, the fund was down roughly 6% over the previous year, with a 52-week range between $128.77 and $157.24. The beta sits at 0.63 with a 14.25% standard deviation over three years - so it's positioned as a medium-risk play. That lower beta actually makes sense given healthcare's defensive characteristics.

The dividend yield came in at 1.72%, which isn't spectacular but reasonable for the sector. The fund carries a Zacks ETF Rank of 1 (Strong Buy), which is based on expected returns, costs, and momentum factors.

If you're comparing options in the healthcare industry etf category, there's also the Vanguard Health Care ETF (VHT) with $15.41 billion in assets and a 0.09% expense ratio, plus iShares Global Healthcare ETF (IXJ) at $3.81 billion with a 0.41% ratio. But XLV's ultra-low costs and massive scale make it a solid core holding if you want straightforward healthcare sector exposure.

Bottom line - if you're looking to build healthcare industry etf exposure for the long term, XLV's low fees and diversification across pharmaceuticals, providers, equipment makers, and biotech companies make it worth considering. The sector's defensive nature appeals to a lot of investors right now too.